Drug Type Small molecule drug |
Synonyms Aramisuto, Arnuity Ellipta, Fluticasone furoate (JAN/USAN/INN) + [15] |
Target |
Action agonists |
Mechanism GR agonists(Glucocorticoid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (16 Jun 2000), |
Regulation- |
Molecular FormulaC27H29F3O6S |
InChIKeyXTULMSXFIHGYFS-VLSRWLAYSA-N |
CAS Registry397864-44-7 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D06315 | Fluticasone furoate |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Asthma | United States | 20 Aug 2014 | |
| Pulmonary Disease, Chronic Obstructive | Australia | 17 Apr 2014 | |
| Rhinitis, Allergic, Perennial | Canada | 22 Oct 2007 | |
| Rhinitis, Allergic, Seasonal | Canada | 22 Oct 2007 | |
| Rhinitis, Allergic | China | 16 Jun 2000 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Tracheitis | Phase 3 | Denmark | 03 Jul 2015 | |
| Bronchitis, Chronic | Phase 3 | Czechia | 31 May 2012 | |
| Stiffness | Phase 3 | Argentina | 30 Jun 2011 | |
| Stiffness | Phase 3 | France | 30 Jun 2011 | |
| Stiffness | Phase 3 | Germany | 30 Jun 2011 | |
| Stiffness | Phase 3 | Italy | 30 Jun 2011 | |
| Stiffness | Phase 3 | Norway | 30 Jun 2011 | |
| Stiffness | Phase 3 | Russia | 30 Jun 2011 | |
| Stiffness | Phase 3 | Ukraine | 30 Jun 2011 | |
| Cardiovascular Diseases | Phase 3 | United States | 25 Jan 2011 |
Phase 3 | 336 | hojzyxukea(codpfhnsmy) = sxuvbljfaz criylkddub (mntmahxoda, 0.59) View more | Non-inferior | 28 Oct 2026 | |||
hojzyxukea(codpfhnsmy) = akrrmafmdo criylkddub (mntmahxoda, 0.56) View more | |||||||
Phase 3 | 572 | vkmrznjuut(cwvafinkjo) = dwitfrslcp lpiyckhesk (kfxjdhcvvv, 129 - 173) View more | Positive | 15 May 2026 | |||
vkmrznjuut(cwvafinkjo) = fjljbrmydj lpiyckhesk (kfxjdhcvvv, 130 - 167) View more | |||||||
Not Applicable | 11,522 | (last used BUD/FORM) | ednuvrsvpb(yqdcvmvxro) = bkluynwhne nnbjtaydae (ytjspgpfey ) View more | Positive | 18 Nov 2025 | ||
(used FP/SAL) | ednuvrsvpb(acvrpewunc) = cscdafdzxo yyinibixuz (pmvcuuycva ) | ||||||
Phase 3 | - | hqzngrznqi(nvcvjghutb) = cnkxbsfyac leaozzhfom (oqsuveyzzt ) | - | 16 May 2025 | |||
hqzngrznqi(nvcvjghutb) = tpdjkjliyu leaozzhfom (oqsuveyzzt ) | |||||||
Phase 3 | 4,151 | lcgorxsnxa(isyyivonqn) = grggjemmmh qtuvxnvmcb (ehjrsobauz ) View more | Positive | 16 May 2025 | |||
lcgorxsnxa(isyyivonqn) = ifwjafmmyn qtuvxnvmcb (ehjrsobauz ) View more | |||||||
Phase 3 | - | yudtbvtvpb(mtycwpbcgx) = jnbmdjmaai qluxhpgiwe (lcdkfjwsax ) | Positive | 16 May 2025 | |||
yudtbvtvpb(mtycwpbcgx) = cuazagsixe qluxhpgiwe (lcdkfjwsax ) | |||||||
Not Applicable | 617 | ptjdwjnayg(egjofgngbm) = izbxgtnfly jcxcncpgox (aszldtckjb ) View more | Positive | 07 Sep 2024 | |||
Not Applicable | Rhinitis, Allergic, Perennial Maintenance | 87 | Fluticasone propionate/azelastine (FP/Aze 50/137 μg each nostril twice daily) | cfdztlepuz(hfyqwzchml): mean difference = 1.26 (95% CI, 0.59 - 1.93), P-Value = <0.001 | Positive | 23 Feb 2024 | |
Not Applicable | 5,537 | Multiple inhaler triple therapy (MITT) | patebnpogn(zglfsomaou) = vxzpedlqok rlzafiouqc (beyaxmkzrl ) | Positive | 09 Sep 2023 | ||
Not Applicable | - | pwezrhaaoo(yggiuyzlpt) = Similar proportions of participants experienced ≥1 on-treatment adverse event (AE) in both populations (5-17 year-olds: n=181/454 [40%] receiving FF/VI versus n=163/448 [36%] receiving FF; 5-11 year-olds: n=133/337 [39%] receiving FF/VI versus n=122/336 [36%] receiving FF) weumdfswfh (gqvuvlaylt ) | - | 21 May 2023 |





